Professor of Veterinary Clinical Genetics Royal Veterinary College London, England, United Kingdom
Disclosure(s):
Lucy J. Davison, MA VetMB PhD DSAM DECVIM: No relevant disclosure to display
Presentation Description / Summary: This presentation will explore the reasons why some cats are susceptible to Feline Infectious Peritonitis (FIP) and others are not. In the first part of the presentation, new data will be presented relating to host genetics - highlighting host genetic variants that are associated with an increase in FIP risk. The second part of the presentation will consider the virus itself and show some examples of viral sequences acquired by sequencing the lymph nodes of cats affected with FIP. This will illustrate the role of viral mutation in FIP development and sequence data will also be compared to the viral sequence from the 2023 FIP outbreak in Cyprus. Finally, the host immune response to the virus across a range of tissues will be presented, using RNA-sequencing data. The key features of the immune response to feline coronavirus will be discussed, including the individual features of each cat which impact on the immune response, such as the MHC genes and the B-cell and T-cell immune repertoire. The session will conclude with reflections on the unanswered questions in FIP and the implications of the new anti-viral treatment strategies now in use.
Learning Objectives:
Upon completion, participant will be able to appreciate in more detail that there are many host genetic factors which influence FIP risk - and understand how these are being discovered.
Upon completion, participant will be able to recognise that although viral mutations are seen in FIP, no single "FIP virus" or "FIP mutation" exists which always causes disease and is present in every case.
Upon completion, participant will be able to understand that the host immune response is partly pre-determined by the immune repertoire and MHC of the cat, but also appreciate that there are some broader immunological features in common across most cats with FIP, such as a type 1 interferon signature.